GlassScriptPhysician profile
Rita Winn
NPI 1972000339
$3,446.65
in general payments reported to CMS, 2019-2025
21 companies · $855 in 2025
The $855 reported for 2025 was more than what 95% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $297 · 2022: $774 · 2023: $675 · 2024: $845 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $959.20 | 2021-2025 | Tivdak |
| Glaxosmithkline, LLC. | $620.86 | 2021-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $450.80 | 2021-2025 | Lynparza, Imjudo |
| Merck Sharp & Dohme LLC | $370.88 | 2021-2025 | Keytruda, Lynparza |
| Eisai INC. | $254.60 | 2022-2025 | |
| Astellas Pharma US INC | $131.07 | 2023-2025 | Veozah |
| Abbvie INC. | $121.32 | 2024-2025 | |
| Tempus Ai, INC | $76.70 | 2024-2025 | Xt Cdx |
| Hologic Sales and Service, LLC | $68.89 | 2021-2024 | Thinprep 2000 Processor, Aptima |
| Seagen INC. | $65.00 | 2023 | Tivdak |
| Myriad Genetic Laboratories, INC. | $47.93 | 2024 | Myrisk |
| Cumberland Pharmaceuticals, INC. | $47.32 | 2022-2025 | Sancuso |
| Daiichi Sankyo INC. | $39.94 | 2024-2025 | Enhertu |
| Edwards Lifesciences Corporation | $37.45 | 2024 | Hemosphere |
| Sumitomo Pharma America, INC. | $33.83 | 2024-2025 | Myfembree |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $31.89 | 2024 | Irrisept |
| Aroa Biosurgery Incorporated | $24.94 | 2024 | |
| Pharmaand Gmbh | $21.44 | 2025 | Rubraca |
| Smith+Nephew, INC. | $20.19 | 2024 | Pico |
| Teleflex LLC | $16.45 | 2022 | |
| Clovis Oncology, INC. | $5.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Winn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.